The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Durvalumab Immunotherapy: Anti-PD-L1 Antibody

Indications in lung cancer, biliary tract and adverse event management

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Durvalumab Immunotherapy: Anti-PD-L1 Antibody?

Durvalumab is a high-affinity human IgG1 antibody that binds PD-L1 and prevents its interaction with PD-1 and CD80.

By unblocking T-cell suppression in the tumor microenvironment it restores cytotoxic activity against cancer cells.

Standard dosing is 10 mg/kg every 2 weeks or 1500 mg every 4 weeks intravenously.

Key indications include consolidation therapy after chemoradiation in unresectable stage III NSCLC (PACIFIC regimen) and combination with chemotherapy in extensive-stage SCLC.

It is also approved combined with tremelimumab and chemotherapy or with gemcitabine-cisplatin for biliary tract cancer and metastatic NSCLC.

Symptoms

Common side effects include cough, fatigue, dyspnea, decreased appetite, rash and pruritus.
Immune-related events may include pneumonitis (a particular concern after thoracic radiation), colitis, hepatitis, endocrinopathies and nephritis.
Infusion reactions are uncommon but include flushing, dyspnea and fever.
Severe events such as myocarditis, encephalitis or severe dermatologic reactions are rare but require immediate attention.
Symptoms can occur during therapy or weeks to months after stopping.

Risk Factors

Recent thoracic radiotherapy increases the risk and severity of immune pneumonitis.
Pre-existing autoimmune disease or interstitial lung disease elevates immune-related toxicity risk.
Active or chronic viral hepatitis should be assessed before starting.
Combination regimens with tremelimumab or chemotherapy increase additive toxicity profiles.
Older patients and those with poor performance status need careful selection and monitoring.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New or worsening cough, shortness of breath, chest pain or oxygen desaturation requires urgent evaluation for pneumonitis.
  • Persistent diarrhea, blood in stool or severe abdominal pain suggests immune colitis.
  • Jaundice, dark urine or right upper quadrant pain warrants prompt liver assessment.
  • Severe fatigue, hypotension, vision changes or polyuria may indicate endocrine toxicity.
  • Skin blistering, mucosal involvement, palpitations, syncope or neurological symptoms require immediate emergency care.

Treatment Methods

01
Grade 1 events are managed symptomatically with continuation of durvalumab under close monitoring.
02
Grade 2 events typically require treatment interruption and prednisone 0.5-1 mg/kg/day with slow taper over at least 4 weeks.
03
Grade 3-4 events generally lead to permanent discontinuation, methylprednisolone 1-2 mg/kg/day and additional immunosuppressants for refractory cases.
04
Endocrinopathies are managed with appropriate hormone replacement; durvalumab can usually be continued.
05
Coordinated care with oncology, pulmonology, gastroenterology, hepatology and endocrinology improves outcomes and limits long-term morbidity.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.